The 86% target precision rate is a strong technical validation of Evaxion's AI platform, which could enhance confidence in its broader pipeline. Traders should monitor the upcoming AACR presentation and anticipate potential partnership interest or follow-on clinical developments. The robust immune response data may reprice expectations for EVX-01's clinical efficacy, especially given the 75% ORR already observed.
Price Chart
Executive Summary
Evaxion A/S announced phase 2 trial data showing its AI-designed personalized cancer vaccine EVX-01 achieved an 86% success rate in triggering tumor-specific immune responses, a key validation of its AI-Immunology platform. The results, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the vaccine's therapeutic potential in advanced melanoma.
Key Facts
- 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, described as a record high
- Durable vaccine-specific immune responses observed over two years
- High de novo T-cell response rate (86%) indicates strong immune system activation
- Positive correlation between AI-prediction scores and immune response magnitude confirmed
- Trial conducted in advanced melanoma patients using EVX-01 in combination with KEYTRUDA (pembrolizumab)
- Two-year clinical data previously showed a 75% Objective Response Rate
- Three-year clinical data expected in H2 2026
Financial Impact
High potential long-term value given platform validation and lead asset advancement; no immediate financials reported
Risk Factors
- Clinical trial results do not guarantee regulatory approval
- Small market cap ($35M) increases volatility risk
- Dependence on future clinical data and external funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002532 |
| Document: f6k_041726.htm | 0001171843-26-002532 |
| Document: 0001171843-26-002532-index-headers.html | 0001171843-26-002532 |
| Document: 0001171843-26-002532-index.html | 0001171843-26-002532 |
| Document: 0001171843-26-002532.txt | 0001171843-26-002532 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access